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This paper describes the effects of dichlorvos (DDVP) on butyrylcholinesterase (BuChE) activity with possible 
consequences for lipid and lipoprotein metabolism in rats. The rats of both sexes were given a single and 
multiple doses of DDVP (8.0 mg/kg body weight) with two–day intervals between administrations, ensuring 
the continuous inhibition of BuChE activity without lethal outcome. BuChE activity was measured in plasma, 
liver, and white and brown adipose tissue. The recovery of BuChE activity was observed only in white 
adipose tissue of female rats 10 days after treatment. Our results show that DDVP significantly decreases 
BuChE activity in female and male rat plasma (40–60%; P<0.05), and significantly increases triglycerides 
(60–600%; P<0.05) and total cholesterol (35–75%; P<0.05). In contrast to the increased HDL–cholesterol 
(20–30%; P<0.05), LDL–cholesterol decreased (30–40%; P<0.05). The decrease of BuChE activity and 
the changes in concentrations of lipids and lipoproteins were observed throughout the experiment. Our 
results contribute to the hypothesis that BuChE may play a role in lipid and lipoprotein metabolism.
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Much is known about the irreversible and direct 
inhibition of the active centre of butyrylcholinesterase 
(BuChE: EC 3.1.1.8, acylcholine acylhydrolase, 
plasma cholinesterase) by organophosphorus 
(OPs) compounds (1, 2). BuChE inhibition is of 
practical importance, because the exposure to OP 
compounds in humans relies on laboratory testing 
of plasma BuChE and red cell acetylcholinesterase 
(AChE: EC 3.1.1.7) activity. Although BuChE is 
synthesised in the liver and is released in blood, 
it has been found in various tissues (e.g. adipose 
tissue, small intestine, lung and the white matter 
of the brain). However, it is not known whether the 
BuChE found in these tissues originates only from 
blood, or it can be synthesised in those tissues as well 
(3–5). BuChE is an enzyme without known biological 
substrate in mammals (6), but it hydrolyses a variety 
of esters including butyrylthiocholine, butyrylcholine, 
propionylthiocholine, propionylcholine, and 
pharmacologically important succinylcholine. It 
has been suggested that BuChE is the precursor 
of AChE in the nervous system, with an important 
role in the regulation of slow impulse conduction in 
the nervous system (7). Pretreatment with purified 
human BuChE has a protective effect in mice, rats, 
and primates exposed to OP compounds (8–10). 
Some authors suggest that BuChE plays a role 
in lipid and lipoprotein metabolism (4, 11–12). 
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In human poisoning with parathion, a decrease 
in BuChE activity correlated with a decrease in 
low–density lipoproteins (LDL–cholesterol) and in 
the total cholesterol concentration (13). With clinical 
recovery, all parameters returned to normal values. 
The hypothesis that LDL–cholesterol is formed from 
very–low density lipoproteins (VLDL–cholesterol) in the 
presence of BuChE (11) is supported by the fact that 
increased BuChE activity is associated with abnormal 
lipid metabolism in humans (14–16). However, the 
data presented by Schouten and co–workers (17) 
challenge this hypothesis, as they show that BuChE 
activity in heterozygous familial hypercholesterolemic 
patients is not related to changes in LDL–cholesterol 
and high–density lipoproteins (HDL–cholesterol).
Similar changes were observed in animals. Fat 
Zucker rats that exhibited a marked increase in 
VLDL–cholesterol had high plasma BuChE activity 
(18–19). Changes in BuChE activity and lipid 
metabolism were found in diabetic and normal rats 
after administration of a specific BuChE inhibitor, 
iso–OMPA (tetraisopropyl pyrophosphoramide) (19). 
Rabbits treated with dichlorvos (2,2–dichlorovinyl 
dimethylphosphate, DDVP) also showed a correlation 
between decreased BuChE activity and lipid and 
lipoprotein concentration (15).
OPs compounds are highly toxic substances that 
have been widely used in agriculture as pesticides 
for many years. A very limited number of them may 
be used as drugs in human and veterinary medicine. 
Metrifonate (Trichlorfon) is used as an antiparasitic 
drug in the treatment of schisostomiasis (20), and 
some clinical trials have shown its effectiveness in 
the therapy of Alzheimer’s disease (21). It is known 
that in a mammalian organism Metrifonate rearranges 
spontaneously at physiological pH to form the highly 
toxic DDVP. On the other hand, the widespread use 
in agriculture and the high vapour pressure of DDVP 
presents a real danger of poisoning for workers 
occupationally exposed to DDVP formulations. DDVP 
is not only esterase inhibitor; according to scarce 
literature data it may also disturb different metabolic 
processes through phospolipase and lipase inhibition 
(15, 22).
Due to quick elimination and long–term inhibition 
of BuChE activity, we considered DDVP appropriate 
for studying the relationship between BuChE activity 
and lipid metabolism. The involvement of BuChE in 
lipid metabolism may be important in the professional 
exposure to DDVP.
By comparing BuChE plasma activity with that 
in the liver and white and brown adipose tissue, we 




Dichlorvos, (2,2–dichlorovinyl dimethylphosphate, 
DDVP); obtained from “Cosmochemia” Otočac, 
Republic of Croatia, purity 93%) was dissolved in 
glycerol formal (methylidinoglycerol; 50.0 mg/ml).
Treatment of animals
Male and female adult Wistar rats (240–280 g body 
weight) were fed on a standard diet for laboratory 
rodents (Sljeme, Zagreb, Republic of Croatia). Animals 
had free access to water and were kept in macrolone 
cages under controlled conditions (room temperature 
21 °C, light and dark cycle exchanging every 12 hours). 
The animals (30 males and 30 females) were randomly 
divided in three control groups (n=5 each), and three 
treated groups (n=5 each). In our preliminary study, 
we established the intraperitoneal (i.p.) DDVP LD50 for 
rats of 16.0 mg/kg body weight. The dose of 12.0 mg 
DDVP/kg body weight (3/4 LD50) resulted with high 
mortality of rats. The dose of 4.0 mg of DDVP/kg 
body weight (1/4 LD50) inhibited only about 10–20% 
of plasma BuChE activity without changes in lipid and 
lipoprotein plasma levels. For this study we chose 1/2 
DDVP LD50 (8.0 mg /kg of body weight) because it 
inhibited about 50% of BuChE activity in rat plasma 
with a 100% survival.
One treated group received a single dose of DDVP 
and was sacrificed 48 h afterwards. Two groups of 
animals were treated twice (at 48 h intervals) and 
sacrificed 48 h and 10 days after the last treatment, 
respectively. The controls were given a solvent 
according to the same experimental schedule.
All animals were sacrificed with coal gas; blood 
samples were obtained directly from the heart, and 
adipose tissue was isolated from the epididymal 
(males) or parametrial (females) fat depot. Liver tissue 
was rinsed with saline. Plasma and tissue samples 
were stored and frozen immediately after sampling at 
–20 °C until further processing. The tissue samples 
were homogenized (200 mg tissue/ml saline) and 
supernatant was obtained by centrifuging for 15 min 
at 2800 G.
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BuChE
The BuChE activity in the plasma and tissues (liver, 
white and brown adipose tissue) was determined by 
spectrophotometry (23) using butyrylthiocholine (0.9 
mM) (Sigma ChemCo, St. Louis, USA) as a substrate. 
Since liver tissue contains BuChE and AChE, the 
BuChE assay was carried out with and without the 
specific BuChE inhibitor ethopropazine hydrochloride 
in final concentration of 1.7 µM (Sigma ChemCo, St. 
Louis, USA). BuChE activity was calculated indirectly 
as the difference of the two measurements. The 
activity of the enzyme is expressed as µmol of 
substrate hydrolysed/min/ml of plasma, i.e. µmol of 
substrate hydrolysed/min/g of tissue. Since there was 
no difference between control groups of the same 
sex in the activity of BuChE either in plasma or in all 
tissues, the mean BuChE activity in all males or in all 
females (n=15) was taken as control value. Relative 
changes in the enzyme activity in the treated animals 
are presented as the percentage of activity of the 
respective control group.
Lipids and lipoproteins
The concentrations of total cholesterol in 
the plasma were determined using a cholesterol 
enzymatic colorimetric test (“Herbos Dijagnostika”, 
Sisak, Republic of Croatia) (24–25). Triglyceride 
concentrations were determined using a triglyceride 
enzymatic colorimetric test – so called GPO–PAP 
method (“Olympus Diagnostica” GmbH, Hamburg, 
Germany) (26–27). HDL–cholesterol levels were 
determined using the method of Burstein and 
co–workers (28). Friedwald’s formula was used 
for calculating LDL–cholesterol levels from total 
cholesterol, triglycerides and HDL–cholesterol values 
(29). The concentrations of lipids and lipoproteins 
were measured in duplicate, and expressed as 
mmol/l of plasma. Since there was no difference in 
the plasma concentration of lipids and lipoproteins 
between control groups of the same sex, the mean 
concentration in all males or in all females was taken as 
control value. Relative changes in lipid and lipoprotein 
concentrations in treated animals are shown as the 
percentage of the respective control group.
Statistical analysis
Data are shown as the mean plus standard 
deviation (SD). The mean, medians and SDs were 
calculated using a software package Statistics® for 
Windows Version 5.0 A. The statistical significance 
was determined by parametric t–test and non–
parametric Kolmogorov–Smirnov two–sample test, 
where appropriate. The differences discussed in this 
paper were considered significant at P<0.05 level of 
significance.
RESULTS AND DISCUSSION
Table 1 shows the results of our BuChE assay in 
plasma, liver, and white and brown adipose tissue 
of male and female rats. In DDVP–treated rats, the 
relative inhibition of BuChE was comparable for 
both sexes (up to 60%) and remained was present 
throughout the study. The decrease in BuChE activity 
in white adipose tissue was significant and was similar 
to the inhibition in the plasma and liver in all but one 
treated group. The inhibition of BuChE activity in the 
adipose tissue was significant in all treated males. In 
female rats treated with a single dose and sacrificed 
48 h later and in female rats treated with two doses 
and sacrificed 48 h after the last treatment the enzyme 
inhibition in the white adipose tissue was 47% and 
70%, respectively, and in the brown adipose tissue 
15% and 35%, respectively. The BuChE activity in the 
adipose tissue collected from female rats treated with 
two DDVP doses and sacrificed 10 days after the last 
treatment did not differ from controls. The recovered 
BuChE activity observed in the last group of female 
rats may be the consequence of estrogenic effect on 
the enzyme synthesis in adipose cells. Namely, it is 
known that in addition to the ovary, sex hormones in 
females synthesise in the adipose tissue. Unlike in 
the adipose tissue, BuChE activity did not recover in 
the liver of either male or female rats after the DDVP 
treatment ended. Our results of BuChE activity assay 
showed that, beside the liver, the synthesis of BuChE 
might occur in the adipose tissue. A relatively poor 
circulation in the adipose tissue may account for 
the weaker effect of DDVP on estrogens and on the 
increase in BuChE activity.
The decrease in plasma BuChE activity and the 
concurrent significant changes in lipid concentrations 
were observed in rats of both sexes after single and 
multiple DDVP treatments. The results are shown in 
Table 2.
It is known that plasma HDL–cholesterol in rats 
is much higher than LDL–cholesterol, and that HDL 
strongly dominates in total cholesterol (30).
The changes in total cholesterol, HDL–cholesterol 
and triglycerides in the plasma of all treated groups 
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of rats do not seem consistent (Table 2). Rats treated 
with multiple doses of DDVP showed a decrease 
in LDL–cholesterol. Our results suggest that the 
changes in BuChE activity affect lipid metabolism in a 
sex–independent manner, and are in accordance with 
the hypothesis published by Kutty and co–workers
(11) that LDL–cholesterol is formed from VLDL in the 
presence of BuChE.
Triglycerides in plasma are decomposed into free 
fatty acids by hepatic and plasma lipoprotein lipase 
(31). According to Kozlowska and co–workers (22), a 
single high oral dose (1/2 LD50) of DDVP significantly 
inhibits lipoprotein lipase activity in rats sacrificed up 
to 48 hours after dosing. Repeated small doses of 
DDVP (1/20 LD50) given consecutively over 10 days 
did not inhibit the activity of lipoprotein lipase, but 
the concentration of lipoprotein fraction increased. 
In our experiment, the increased concentration of 
triglycerides and the inhibition of BuChE activity were 
found in plasma of animals given two doses (with 48h 
interval) of DDVP and sacrificed 2 and 10 days after the 
last treatment. The high affinity of DDVP for esterase 
is well known, and it is possible that lipoprotein lipase 
activity would be inhibited only if a high concentration 
of DDVP is applied. Therefore, it may be assumed that 
changes in lipoprotein concentrations in the period 
of up to 48 hours may be caused by simultaneous 
inhibition of lipoprotein lipase and BuChE activity. It 
seems that the increase in triglyceride concentrations 
found by Kozlowska and co–workers (22) in animals 
Legend: significantly different from controls, * t–test, P<0.01; ** t–test, P<0.001; + Kolmogorov–Smirnov test, P<0.01; ++ Kolmogorov–Smirnov 
test, P<0.001.
Table 1 Catalytic activities and relative changes of BuChE (Mean ± SD) in plasma and tissue of male and female rats after a single dose and two 
doses of DDVP (8.0 mg/kg b.w.; i.p.)
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treated with low doses of DDVP and our own results 
for rats sacrificed 10 days after the termination of 
treatment support the hypothesis that BuChE is 
involved in the metabolism of lipids.
In conclusion, the inhibition of BuChE activity 
seems to be connected with changes in lipid 
metabolism. Judging from experimental animal 
data, we believe that in addition to the measurement 
of BuChE activity, it would be appropriate to control 
lipoprotein levels in workers occupationally exposed 
to DDVP.
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Sažetak
UČINAK DIKLORVOSA NA AKTIVNOST BUTIRILKOLINESTERAZE I METABOLIZAM LIPIDA U 
ŠTAKORA
U radu su opisani učinci diklorvosa (DDVP) na aktivnost enzima butirilkolinesteraze (BuChE) i metabolizam 
lipida i lipoproteina u štakora obaju spolova. Učinci DDVP–a u dozi od 8,0 mg/kg tjelesne težine istraživani su 
poslije primjene jedne i dviju intraperitonealnih aplikacija. Kod ponovljenih aplikacija DDVP je davan svakih 
48 sati kako bi se osigurala kontinuirana inhibicija BuChE u tretiranih životinja, ali bez pojave smrtnosti 
životinja. Aktivnost BuChE izmjerena je u plazmi, jetri te bijelome i smeđem masnom tkivu. Oporavak 
aktivnosti BuChE uočen je samo u bijelom masnom tkivu ženki štakora koje su žrtvovane 10 dana nakon 
zadnjeg tretmana. Nađeno je da DDVP značajno smanjuje aktivnost BuChE u plazmi životinja obaju 
spolova (40–60%; P<0,05) te značajno povećava koncentraciju triglicerida (60–600%; P<0,05) i ukupnog 
kolesterola (35–75%; P<0,05). Za razliku od povećane vrijednosti HDL–kolesterola (20–30%; P<0,05) 
uočen je statistički značajan pad koncentracije LDL–kolesterola (30–40%; P<0,05). Aktivnosti BuChE, 
kao i promjene u koncentracijama lipida i lipoproteina primijećene su tijekom cijelog eksperimenta. Naši 
rezultati govore u prilog hipotezi da BuChE ima važnu logu u metabolizmu lipida i lipoproteina in vivo.
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